Literature DB >> 22110189

Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.

Reinhart Speeckaert1, Nanja van Geel, Rosalie M Luiten, Mireille van Gele, Marijn Speeckaert, Jo Lambert, Karim Vermaelen, Esther P M Tjin, Lieve Brochez.   

Abstract

BACKGROUND/AIM: Regressing nevi are considered an example of an efficient early antitumoral response preventing the development of neoplasia. The underlying mechanism has not been elucidated, although an immune-based destruction of melanocytes is supposed. The aim of this study was to provide evidence of an effective immunosurveillance of pigment lesions in a patient at high risk of melanoma. CASE REPORT: A patient with the dysplastic nevus syndrome and a history of melanoma was included in this study. Since 2003, a marked regression of almost all nevi was observed. Immunohistochemistry was performed and the antigen specificity of T-cells was analyzed on T-cells isolated from a regressing nevus by flow cytometry using HLA-A2-peptide tetramers containing Mart-1(26-35), gp100(280-288), gp100(209-217) and tyrosinase(369-377). Immunohistochemistry of the regressing nevi showed a strong infiltrate of CD4 + and CD8 + T-cells. Flow cytometric analyses demonstrated the presence of a CD8 + T-cell response against gp100(280-288) and Mart-1(26-35) both in peripheral blood and in a regressing nevus.
CONCLUSION: These findings indicate that an immune reaction against melanocyte differentiation antigens can target specifically nevi without signs of vitiligo and suggests that boosting the anti-melanocyte immune response in patients at high risk for melanoma may prevent tumor development at an early stage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22110189

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Melanoma-associated leukoderma - immunology in black and white?

Authors:  Hadas Prag Naveh; Uma N M Rao; Lisa H Butterfield
Journal:  Pigment Cell Melanoma Res       Date:  2013-10-09       Impact factor: 4.693

2.  Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma.

Authors:  Reinhart Speeckaert; Nanja Van Geel; Jo Lambert; Barbara Boone; Ines Chevolet; Mireille Van Gele; Marijn M Speeckaert; Lieve Brochez
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

3.  Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.

Authors:  Enrique Podaza; Ibel Carri; Mariana Aris; Erika von Euw; Alicia Inés Bravo; Paula Blanco; Juan Manuel Ortiz Wilczyñski; Daniel Koile; Patricio Yankilevich; Morten Nielsen; José Mordoh; María Marcela Barrio
Journal:  Front Immunol       Date:  2020-06-05       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.